HB
HBMHF.US HBM Holdings Limited
- Market cap
- USD 1.36B
- P/E
- 13.0x
- P/B
- 3.55x
- ROE
- 62.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is HBMHF.US undervalued?
Graham numberHBMHF.US trades 43.2% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
HBM Holdings Limited fundamental analysis
No fundamental analysis for HBM Holdings Limited yet.
HBM Holdings Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About HBM Holdings Limited
HBM Holdings Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of antibody therapeutics focusing on immunology and oncology in Mainland China, the United States, Europe, and internationally. It develops the Harbour Mice Platform, which generates human monoclonal antibodies in two heavy and two light chain H2L2 and heavy chain formats. The company is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively …
Full company profileHBM Holdings Limited financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
HBM Holdings Limited annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 1.48M | 5.45M | 14.1M | 4.29M | 40.8M | 89.5M | 38.1M | 158M | 489M |
| Gross Profit | 836K | 676K | 8.43M | -2.63M | 32.6M | 87.5M | 33.6M | 147M | 456M |
| Operating Income | -37.1M | -55.7M | -81.3M | -143M | -122M | 21.8M | -2.19M | 80.7M | 268M |
| EBITDA | -33.0M | -63.2M | -291M | -131M | -127M | 31.2M | 10.2M | 83.2M | 277M |
| Net Income | -34.6M | -67.8M | -296M | -137M | -138M | 22.8M | 2.78M | 91.5M | 259M |
| EPS | -0.05 | -0.09 | -0.39 | -0.19 | -0.19 | 0.03 | 0.00 | 0.11 | 0.31 |
| Balance Sheet | |||||||||
| Total Assets | 83.5M | 69.5M | 389M | 282M | 232M | 228M | 215M | 500M | 533M |
| Total Liabilities | 169M | 223M | 27.7M | 59.4M | 139M | 109M | 91.0M | 133M | 115M |
| Shareholders' Equity | -85.9M | -153M | 361M | 223M | 92.7M | 120M | 124M | 367M | 418M |
| Cash & Short-term Investments | 60.3M | 33.8M | 357M | 216M | 172M | 141M | 167M | 402M | 359M |
| Total Debt | - | 204M | 1.73M | 19.5M | 90.8M | 66.0M | 61.3M | 81.8M | 89.7M |
| Cash Flow | |||||||||
| Operating Cash Flow | -33.3M | -45.9M | -34.6M | -123M | -98.7M | -19.1M | 30.7M | 81.3M | -36.5M |
| Capital Expenditure | 4.87M | 13.3M | 603K | 14.2M | 18.5M | 2.48M | 235K | 11.8M | 12.9M |
| Free Cash Flow | -38.2M | -59.1M | -35.2M | -137M | -117M | -21.6M | 30.4M | 69.6M | -49.4M |
| Ratios | |||||||||
| ROE | - | - | -82.1% | -61.5% | -148.3% | 19.0% | 2.2% | 24.9% | 62.0% |
| ROA | -41.4% | -97.6% | -76.3% | -48.6% | -59.3% | 10.0% | 1.3% | 18.3% | 48.5% |
| Net Profit Margin | -2,332.0% | -1,244.9% | -2,101.1% | -3,198.2% | -337.5% | 25.5% | 7.3% | 57.8% | 53.0% |
| Debt to Equity | - | - | 0.00x | 0.09x | 0.98x | 0.55x | 0.49x | 0.22x | 0.21x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
HBM Holdings Limited dividends
HBM Holdings Limited has not paid dividends in the last 8 fiscal years.
Who owns HBM Holdings Limited
- Insiders 16.15%
- Institutions 22.82%
- Public & others 61.03%
- Shares outstanding 869M
- Free float 528M
HBM Holdings Limited company profile
- Company name
- HBM Holdings Limited
- Ticker
- HBMHF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 327
- Fiscal year end
- December
- Address
- Building A3, Suzhou, China, 215123
- Phone
- 86 512 6579 0025
- Website
- harbourbiomed.com
About HBM Holdings Limited
HBM Holdings Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of antibody therapeutics focusing on immunology and oncology in Mainland China, the United States, Europe, and internationally. It develops the Harbour Mice Platform, which generates human monoclonal antibodies in two heavy and two light chain H2L2 and heavy chain formats. The company is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds and inhibits the neonatal fragment crystallizable receptor for treating myasthenia gravis; Porustobart HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4 for treating melanoma, colorectal cancer, hepatocellular carcinoma, and neuroendocrine neoplasm. It is developing HBM7020 for treating hepatocellular carcinoma and autoimmune diseases; HBM9378 for the treatment of asthma and chronic obstructive pulmonary disease; and HBM1020, HBM7022, HBM7008, HBM9027, HBM7004, and HBM9033 for treating solid tumors. The company has a strategic collaboration with Evinova to apply AI and digital technologies to enhance the efficiency of biologics development. The company was incorporated in 2016 and is based in Suzhou, the People's Republic of China.
HBM Holdings Limited management
10- Dr. Jingsong Wang M.D., Ph.D.Founder, Chairman & CEO · born 1965
- Mr. Youchen ChenVP, CFO, Executive Director & Investor Relations
- Ms. Veronica XiaGlobal COO & China General Manager-Harbour Medical
- Dr. Ian Y. LiuSenior VP & Global Head of Legal, Joint Company Secretary, Executive Director
- Dr. Peter F. Moesta Ph.D.Member of Scientific Advisory Board & Chief CMC Advisor
- Dr. Steve Arkinstall DPhilChief Scientific Advisor
- Mr. Michael D. PattenChief Strategy Officer & Head of Global Alliance
- Dr. Jenny XieChief Scientific Officer for Immunology & Head of Global External Innovation
- Dr. Bob ZhangPresident of Metabolic Disease Franchise
- Dr. Eric Liu Ph.D.COO & Head of Clinical Development - Neuroscience